Citigroup
MRVI icon

Citigroup’s Maravai LifeSciences MRVI Stock Holding History

Citigroup’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Sell
484,236
-37,806
-7% -$128K ﹤0.01% 2911
2025
Q4 		$1.7M Buy
522,042
+199,660
+62% +$672K ﹤0.01% 2771
2025
Q3 		$925K Buy
322,382
+76,170
+31% +$194K ﹤0.01% 3209
2025
Q2 		$593K Buy
246,212
+155,701
+172% +$327K ﹤0.01% 3523
2025
Q1 		$200K Sell
90,511
-26,185
-22% -$103K ﹤0.01% 4199
2024
Q4 		$636K Buy
116,696
+6,086
+6% +$39.2K ﹤0.01% 3664
2024
Q3 		$919K Buy
110,610
+52,580
+91% +$455K ﹤0.01% 3328
2024
Q2 		$415K Sell
58,030
-142,788
-71% -$1.23M ﹤0.01% 3505
2024
Q1 		$1.74M Buy
200,818
+127,130
+173% +$860K ﹤0.01% 2548
2023
Q4 		$483K Sell
73,688
-107,878
-59% -$697K ﹤0.01% 3427
2023
Q3 		$1.82M Sell
181,566
-2,159,294
-92% -$23.7M ﹤0.01% 2064
2023
Q2 		$29.1M Sell
2,340,860
-84,158
-3% -$1.14M 0.02% 659
2023
Q1 		$34M Buy
2,425,018
+578,343
+31% +$8.31M 0.02% 556
2022
Q4 		$26.4M Sell
1,846,675
-190,079
-9% -$2.99M 0.02% 670
2022
Q3 		$52M Buy
2,036,754
+531,213
+35% +$13.3M 0.04% 365
2022
Q2 		$42.8M Sell
1,505,541
-19,681
-1% -$623K 0.03% 439
2022
Q1 		$53.8M Buy
1,525,222
+247,667
+19% +$8.3M 0.03% 469
2021
Q4 		$53.5M Buy
1,277,555
+393,133
+44% +$15.9M 0.03% 540
2021
Q3 		$43.4M Buy
884,422
+831,237
+1,563% +$40.5M 0.03% 595
2021
Q2 		$2.22M Buy
53,185
+45,093
+557% +$1.75M ﹤0.01% 2591
2021
Q1 		$288K Buy
8,092
+7,425
+1,113% +$246K ﹤0.01% 3814
2020
Q4 		$19K Buy
+667
New +$18.6K ﹤0.01% 6681

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's MRVI Position: Q1 2026 in Review

Citigroup reduced its Maravai LifeSciences (MRVI) stake by 7.2% in Q1 2026, selling an estimated $128K and leaving 484,236 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

Citigroup first reported a position in MRVI in Q4 2020 and has held it in 22 quarters since. The position peaked at $53.8M in Q1 2022. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Citigroup held 484,236 shares of Maravai LifeSciences worth $1.37M as of Q1 2026.
  • Citigroup sold 37,806 Maravai LifeSciences shares in Q1 2026, an estimated $128K.
  • Maravai LifeSciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2911 holding.
  • Citigroup first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Maravai LifeSciences position peaked at $53.8M in Q1 2022.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.